1) Participants with low- and high-grade gliomas were less likely to report any allergy; 2) Antihistamine use, independent of allergy status, may not influence glioma risk; 3) Age when diagnosed and years since diagnosis of allergies were not associated with glioma risk.
Yosef Shiloh, Ph.D., a David and Inez Myers professor in cancer research in the department of human molecular genetics and biochemistry in the Sackler School of Medicine at Tel Aviv University, Israel, will receive the 51st Annual AACR G.H.A. Clowes Memorial Award for his studies of the cellular DNA damage response and the rare genomic instability syndrome ataxia-telangiectasia (A-T).
The AACR 102nd Annual Meeting 2011 attracts world leaders in cancer research and treatment, including clinical oncologists, basic scientists, translational researchers and epidemiologists, who are working to improve prevention, diagnosis and patient care with the ultimate goal of eradicating cancer
Pier Paolo Pandolfi, M.D., Ph.D., is the recipient of the 2011 Pezcoller Foundation-AACR International Award for Cancer Research for his outstanding work in the field of cancer genetics and mouse models for cancer. This work has contributed to new therapies for treating cancers.
1) Head and neck cancer accounts for 650,000 new cancer cases each year; 2) Data provide insight into novel mechanisms underlying head and neck cancer; 3) Potential new targets for chemoprevention identified.
Stand Up To Cancer (SU2C), the charitable initiative generating public awareness of and support for ground-breaking research aimed at getting new cancer treatments to patients in an accelerated timeframe, has acquired the TV and film rights to The Emperor of All Maladies: A Biography of Cancer, written by Siddhartha Mukherjee and published by Scribner in November, 2010. The book traces the history, or biography, of the disease from its first appearance thousands of years ago through the Nixon era War on Cancer 40 years ago to today’s promising new directions in cancer medicine.
1) Early research suggests that the immune system can affect angiogenesis; 2) Manipulation of angiogenesis is a key therapeutic strategy for cancer.
1) Use of aromatase inhibitors in early-stage breast cancer patients affected. 2) Older women more likely to discontinue early because of high co-payments. 3) Primary care physician involvement, quantity of other prescriptions affect use.
1) Weight of babies exposed to intrauterine chemotherapy tended to be higher; 2) More malformations were found, regardless of treatment; 3) Multidisciplinary team should be part of pregnant patient’s cancer management.
1) Possible new treatment option for early HER2-negative breast cancer; 2) Safety data, published earlier this year, indicated bevacizumab was feasible; 3) Data on response and surgical outcomes to be presented at symposium.
1) High-dose chemotherapy and autologous stem cell transplantation is effective therapy; 2) Therapy may release cancer stem-like cells from bone marrow; 3) Patients who had low circulating tumor cells did well.
1) Denosumab may be a safe, effective alternative to zoledronic acid; 2) Drug is easy to administer via subcutaneous injection; 3) Dose adjustments or renal monitoring is not required.
1) Predictive value independent of serum tumor markers. 2) CTCs are independent prognostic marker for metastatic disease.
1) Blood was tested after surgery and before chemotherapy. 2) Risk was apparent with just one CTC in the blood. 3) More individualized treatment approaches might be possible based on CTC characterization.
1) Three drug combination worked better than when used alone. 2) Surgical remission rate was 50 percent, but was 20 percent with single therapy.
1) Adding pertuzumab to trastuzumab and docetaxel eradicated tumors. 2) Some tumors were eradicated without chemotherapy.
1) Researchers compared traditional neoadjuvant therapy with new combination of chemotherapy and lapatinib. 2) Histological and surgical outcome results after neoadjuvant therapy presented.
The American Association for Cancer Research commends the U.S. Office of the Surgeon General for its continued focus on tobacco, one of most pressing public health issues of our time. The Surgeon General today released a new report, How Tobacco Smoke Causes Disease, that details the scientific evidence on how smoking causes cancer and numerous other diseases.
1) Largest bisphosphonate trial to date, consisting of 3,360 patients; 2) Detailed analysis defined role in menopausal/post-menopausal women; 3) Press conference to be held on Dec. 9 at 12:30 p.m. CT.
1) Exemestane and anastrozole provide similar control of breast cancer and survival with different side effect profiles; 2) Exemestane may be considered as an alternative, first-line adjuvant therapy.
1) Exogenous estrogen (administered as HRT) reduces breast cancer rates. 2) HRT based on estrogen alone helps manage menopausal symptoms. 3) More data are needed to elaborate on estrogen’s role in chemoprevention.
1) Increased risk for cardiovascular disease appears to be a drug class effect; 2) Risk is small in general population, but may be high in patients with risk factors; 3) Switching to aromatase inhibitors after tamoxifen use may decrease mortality unrelated to breast cancer.
1) Only 50 percent of women get regular mammograms; 2) Analysis conducted in an insured population; 3) Reason for low mammography rates is unknown.
1) Obesity was associated with inferior survival in women with stage I to III breast cancer; 2) Women with ER-positive/HER2-negative disease had inferior outcomes; 3) Research is needed to identify contributing factors and develop therapeutic interventions.
George W. Sledge Jr., M.D., a nationally recognized pioneer in the development of novel therapies for breast cancer, will receive the 2010 William L. McGuire Memorial Lecture Award at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
The American Association for Cancer Research commends the U.S. Department of Health and Human Services (HHS) on the establishment of science-based, 10-year objectives to reduce the incidence of cancer, which was included as part of the Healthy People 2020 initiative that launched yesterday.
Experts present the latest research in breast cancer treatments and life-saving strategies.
The American Association for Cancer Research, in cooperation with the University of Catania Ph.D. Oncology Program and the Italian League Against Cancer of Catania, announces the establishment of the "Margaret Foti Award" for the best thesis in translational oncology. The first awards will be given on Dec. 2, 2010, in Catania, Italy.
Foremost international meeting highlights breakthroughs in cancer research: Orlando, Fla., April 2-6, 2011.
The 33rd CTRC-AACR San Antonio Breast Cancer Symposium will feature the latest findings in prevention, epidemiological, laboratory, translational and clinical breast cancer research. This year’s symposium will highlight new therapies in the pipeline, new approaches with existing agents and emerging biology that will affect the quest for personalized medicine.
The 33rd CTRC-AACR San Antonio Breast Cancer Symposium will feature the latest findings in prevention, epidemiological, laboratory, translational and clinical breast cancer research. This year’s symposium will highlight new therapies in the pipeline, new approaches with existing agents and emerging biology that will affect the quest for personalized medicine.
1) Only one-third of female teens complete the three-dose vaccine series; 2) Young women and black women are least likely to complete the series.
1) Decreased risk of lymphoma, melanoma and endometrial cancer found; 2) More research is needed to confirm lower risk of these cancers.
1) History of fracture, comorbid conditions increase risk of fracture after treatment; 2) Orchiectomy linked to higher fracture risk than use of gonadotropin-releasing hormone.
1) Ninety percent of children had tobacco carcinogens in their urine; 2) Exposure was linked to lack of smoking restrictions in the home; 3) Black children were especially affected.
1) Cancer affects one in three women in the United States; 2) Media conference to focus on new research that affects women.
1) Observed risk present in those who currently use hormone therapy; 2) Risk levels did not differ by type of hormone therapy; 3) Former hormone therapy use not linked to increased risk.
1) Aromatase inhibitors result in an estrogen-deficient state; 2) Estrogen-deficient state increases occurrence of side effects; 3) Side effects may decrease treatment adherence.
1) Association was seen in all women, regardless of weight; 2) Exercising more than 150 minutes per week showed benefit; 3) Endometrial cancer risk was reduced by 34 percent.
1) Soy isoflavones are found in deli meats, breads and vegetables; 2) Decreased risk of low-grade and large tumors found with use.
1) Connection between smoking and breast cancer death had been unclear; 2) Risk existed independent of socioeconomic, clinical and life-style factors; 3) BMI, molecular breast cancer subtype and menopausal status modified risk.
1) Adult weight gain reduced risk for breast cancer; 2) Association may be due to shorter duration of estrogen exposure.
1) Lung tumors in never-smokers harbor alterations distinct from smokers; 2) EGFR mutations are not the only ones driving never-smoker lung cancer; 3) Smokers’ tumors may arise through different molecular mechanisms.
1) Duration and type of statin did not affect risk; 2) Statin use did not affect tumor location or stage.
1) Conference held Nov. 7-10, 2010, at the Philadelphia Convention Center; 2) Press conference on Nov. 8 will focus on chemoprevention; 3) Press conference on Nov. 9 will highlight research in women’s health.
1) Researchers measured the effect on neoplasm, or early-stage disease; 2) Chemopreventive may be of use in high-risk patients.
1) Chemoprevention trials currently lack biomarker measures; 2) Researchers tested protein network signaling in women.
1) The drug has a long-standing safety profile; 2) It could be an inexpensive chemoprevention method; 3) Decreased levels of colorectal cancer biomarker Ki67 was observed.
1) Study adds to evidence that psychosocial stress affects cancer risk; 2) Brief maternal separation did not have the same effect; 3) Prolonged separation increased ER alpha expression in mammary glands.
Despite innovative cancer research being presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, as well as numerous other conferences organized by the American Association for Cancer Research each year, the pace of scientific discovery in cancer research will slow if Congress does not pass the pending appropriations bill for fiscal year 2011.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right